<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 27, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041755</url>
  </required_header>
  <id_info>
    <org_study_id>MI09-002</org_study_id>
    <nct_id>NCT01041755</nct_id>
  </id_info>
  <brief_title>Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.</brief_title>
  <official_title>The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Regional para el Estudio de las Enfermedades Digestivas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Regional para el Estudio de las Enfermedades Digestivas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy is caused by the effects on the brain of substances that under normal&#xD;
      circumstances are efficiently metabolized in the liver. The hyperammonemia is the main factor&#xD;
      responsible for the development of hepatic encephalopathy. In patients with cirrhosis, the&#xD;
      reduction in hepatocellular function and generation of portosystemic shunts contribute to&#xD;
      increase serum ammonium. The current therapeutic approaches, are aimed at reducing blood&#xD;
      ammonium levels.&#xD;
&#xD;
      Administration of the non-absorbable disaccharides, have become standard treatment of hepatic&#xD;
      encephalopathy.There are no adequate clinical trials comparing the efficacy of&#xD;
      L-Ornithine-L-Aspartate (LOLA) infusion against lactose enemas in the treatment of acute&#xD;
      hepatic encephalopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main impact of hepatic encephalopathy in patients with cirrhosis is not related to costs,&#xD;
      but its association with decreased survival and quality of life and should therefore clearly&#xD;
      established the effectiveness of therapeutic interventions used in this disorder.&#xD;
&#xD;
      At the end of the nineteenth century to the ammonium was identified as the main agent&#xD;
      responsible for the development of the syndrome of hepatic encephalopathy. Since then,&#xD;
      reduced nitrogen compounds from the intestine are considered the main therapeutic measure. On&#xD;
      this conceptual base, nonabsorbable disaccharides are the first line therapy in hepatic&#xD;
      encephalopathy.&#xD;
&#xD;
      Current knowledge indicates that other organs such as muscle, brain and kidney are involved&#xD;
      in the generation of ammonium, which has set the pace for the development of new treatments,&#xD;
      able to act systemically in metabolism and elimination of ammonia . L-ornithine L-aspartate&#xD;
      (LOLA) lowers ammonium concentrations in animal and humans models with hyperammonemia. There&#xD;
      are no adequate clinical trials comparing the efficacy of LOLA infusion against lactose&#xD;
      enemas in the treatment of acute hepatic encephalopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained improvement of at least one grade in mental state based on the West Haven criteria</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of hepatic encephalopathy assessed by the West Haven criteria</measure>
    <time_frame>before intervention, 24, 48, and 72 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of hepatic encephalopathy assessed by the Glasgow Coma Scale</measure>
    <time_frame>before intervention, 24, 48, and 72 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of hepatic encephalopathy assessed by the Clinical Hepatic Encephalopathy Staging Scale (CHESS)</measure>
    <time_frame>before intervention, 24, 48, and 72 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in venous ammonia levels</measure>
    <time_frame>before intervention, 24, 48, and 72 hours after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in electroencephalographic tracing</measure>
    <time_frame>before intervention and 72 hours after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Intravenous infusion of L- Ornithine L- Aspartate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a) 20 g L-ornithine-L-aspartate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose enemas</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>b) 20% Lactose enemas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-ornithine-L-aspartate</intervention_name>
    <description>a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.</description>
    <arm_group_label>Intravenous infusion of L- Ornithine L- Aspartate</arm_group_label>
    <other_name>LOLA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose</intervention_name>
    <description>a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.</description>
    <arm_group_label>Lactose enemas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with cirrhosis of any etiology, diagnosed by ultrasound,clinical and / or&#xD;
             histologic criteria&#xD;
&#xD;
          -  Patients over 18 years and under 75&#xD;
&#xD;
          -  Patients with hepatic encephalopathy grade 3-4 according to the criteria of West Haven&#xD;
&#xD;
          -  Patients with hyperammonemia &gt;35 µmol/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of other neurological or psychiatric abnormality&#xD;
&#xD;
          -  Renal failure (serum creatinine greater than 3 mg / dL)&#xD;
&#xD;
          -  Use of drugs affecting the central nervous system&#xD;
&#xD;
          -  Withdrawal Syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Bosques, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Regional para el Estudio de las Enfermedades Digestivas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudia Isabel Blanco Vela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Juárez de México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario &quot;José Eleuterio González&quot;</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>December 31, 2009</study_first_submitted>
  <study_first_submitted_qc>December 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Juarez de Mexico</investigator_affiliation>
    <investigator_full_name>Dr. Claudia Isabel Blanco Vela</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Encephalopathy</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

